Teiko.bio is a technology company.
Teiko.bio has raised $12.0M across 1 funding round.
Teiko.bio has raised $12.0M in total across 1 funding round.
Teiko.bio has raised $12.0M in total across 1 funding round.
Teiko.bio's investors include Andreessen Horowitz, Gradient Ventures, Master Ventures Investment Management.
Teiko.bio is a biotechnology company founded in 2020 and headquartered in Salt Lake City, Utah, specializing in high-dimensional cytometry services for clinical trials.[1][4][5] It provides mass cytometry and spectral flow cytometry to detect immune subsets and states, offering customizable panels like the TokuProfile (35+ markers), whole blood preservation via TokuKit, data analysis dashboards, and curated reports to support immunotherapy development, biomarker discovery, and immune profiling.[1][2][3][5] Serving pharmaceutical companies, biotech firms, and researchers in immuno-oncology and precision medicine, Teiko addresses the challenge of measuring immune responses in blood to predict patient outcomes, personalize treatments, and improve clinical trial efficiency—processing over 5,000 specimens across 25+ Phase I-IV trials with <5% run-to-run variation in its CLIA-registered lab.[4][5][6] With 13-15 employees and seed funding from investors like Tau Ventures, the company has shipped 3,000+ TokuKits and powers global trials in the US, EU, and Australia.[2][4][5]
Teiko.bio emerged at the end of 2020 from the vision of founders addressing gaps in immunotherapy trials, where blood-based immune profiling could predict responses more effectively than tumor-focused approaches alone.[3] Ramji Srinivasan, a Stanford MBA and Paralympics silver medalist, serves as Founder and CEO, while Matt Spitzer, an Assistant Professor at UCSF with a PhD in Immunology, is a co-founder and Chief Scientific Officer; the team includes PhD experts in flow cytometry and immunology from Stanford.[3][4][7] The idea gained traction through early seed investment from Tau Ventures, which highlighted the team's execution focus and the need for personalized immune "fingerprints" via rapid on-site analysis of blood cells.[3] Pivotal early moments included leveraging Altitude Lab's infrastructure in Salt Lake City for lab space, shipments, and scaling—allowing faster operations post-university—and rapid customer pipeline development, leading to CLIA lab setup and global trial support.[2][4]
Teiko.bio stands out in immune measurement through these key strengths:
Teiko.bio rides the personalized medicine and immunotherapy boom, where immune system analysis in blood is increasingly validated for predicting trial success amid a shift from tumor-centric views—unlocking better outcomes in a $22B market for clinical immune measurement.[3][6] Timing aligns with surging demand for biomarkers in immuno-oncology trials, fueled by AI-driven drug discovery (e.g., Recursion's TechBio platform in Utah's BioHive hub) and post-2024 funding waves for local startups.[1][5] Market forces like rising Phase I-IV trial complexity and need for reproducible, global-scale data favor Teiko's plug-and-play tools, reducing costs and "putting 100+ years back on the clock" for developers.[5][6] It influences the ecosystem by standardizing immune profiling, enabling data integration for precision therapies, and fostering Utah's biotech cluster through Altitude Lab collaborations.[1][2]
Teiko.bio is poised for expansion with its CLIA-validated platform powering dozens of trials and a growing TokuKit shipment base, likely attracting Series A funding amid 2025 Utah biotech momentum.[1][2][5] Trends like AI-enhanced cytometry analysis, expanded immunotherapy pipelines, and global trial harmonization will amplify its role, potentially evolving from service provider to full-stack immune intelligence platform with deeper pharma partnerships. As immune measurement becomes trial-standard, Teiko could redefine personalized oncology, scaling from Salt Lake City to capture broader precision medicine demand—building on its foundational insight that the immune system is in our blood.[2][3][5]
Teiko.bio has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in October 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2021 | $12.0M Series A | Andreessen Horowitz, Gradient Ventures, Master Ventures Investment Management |